Biomarin: Interest in new dwarfism drug for children exceeds expectations

Following European approval, interest in Biomarin's treatment for children with achondroplasia, Voxzogo, beats company expectations, it reports. US approval could be coming next month.
Photo: Rob Acket/EMA
Photo: Rob Acket/EMA

Ascendis might gain strong competition in the shape of Biomarin's new treatment for achondroplasia, also known as dwarfism.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading